function, as a guide to predict energetically favourable positions of new NNIs in the NNI binding site of RT. We have reported the synthesis of a series of potent compounds that abrogated HIV replication in peripheral blood mononuclear cells (PBMCs) at nanomolar concentrations without evidence of cytotoxicity (Vig et al., 1998a; Sudbeck et al., 1998; Mao et al., 1998) . In the present study we applied this modelling procedure to design effective compounds against clinically observed drug-resistant HIV-1 isolates and compared the effectiveness of two classes of NNIs; phenethylthiazolylthiourea (PETT) compounds Cantrell et al., 1996; Ahgren et al., 1995; Heinisch et al., 1997) and thioalkylbenzylpyrimidine (S-DABO) compounds (Danel et al., 1997 (Danel et al., , 1998 Mai et al., 1997; Sudbeck et al., 1998; Vig et al., 1998b) . In addition, we report an analysis of a structural basis for NNI resistance and relate it to the observed anti-HIV activities of two different classes of NNIs.
Introduction Figure 1. Structures of several different anti-HIV compounds

Materials and Methods
Composite NNI binding pocket
The procedure used to construct the composite NNI binding pocket, which takes into account information from nine different crystal structures of HIV RT inhibitor complexes, has been described previously (Vig et al., 1998a) .
Docking and K i prediction
Fixed docking in the Affinity program within Insight II (Molecular Simulations, 1996) , as recently described Sudbeck et al., 1998; Vig et al., 1998a,b) , was used for docking into the NNI binding site of RT, which was taken from a crystal structure (Protein Database code 1rev, RT/9-Cl-TIBO complex) (Ren et al., 1995a) . Each final docking position was evaluated by a score function in LUDI. The top scoring model was then compared with the composite binding pocket and the known crystal structure of similar compounds and used for further analyses. We imposed several modifications previously described during the calculation of inhibitory constants (K i values) of the positioned compounds (Vig et al., 1998a) . The working modification of the LUDI scoring function for the PETT compounds previously reported included subtracting a penalty score of P from the total LUDI score when the ring plane of the aromatic residues such as Y181, Y188 or W229 were within 5-7 Å from a group R. Similarly, the Y181C mutation not only results in diminished van der Waals contact with NNI compounds (which has been accounted for in the LUDI score), but it also should be penalized for the unfavourable interaction between the SH group of cysteine and the aromatic ring of the NNI compound. In this case, the penalty P would be applied as follows: LUDI score=MS×BS×2.93+85 (H-bond)-NR×24.2-100-P. Where: MS, molecular surface area of inhibitor molecule; BS, buried surface area of inhibitor molecule (percentage of molecular surface in contact with target protein); NR, number of rotatable bonds in inhibitor molecule; P, score penalty. Where: P=200 when R=hydrophilic group, for example -OH, -SH or -NO 2 ; P=100 when R=halogen atom, for example -F, -Cl, or -Br; P=50 when R=methoxy group, for example -OMe; P=0 when R=hydrophobic group, for example H, CH 3 .
Consequently, the K i values for our modelled compounds were more predictable than they would be otherwise without the scoring modification (Bohm, 1992 (Bohm, , 1994 .
Analysis of van der Waals contact between the NNI compounds and RT V106A mutant
The GRASP program (Nicholls, 1991) was used to perform the calculation and analysis of the van der Waals contact loss because of the V106A mutation of RT based on the crystal structures of RT-nevirapine (Ren et al., 1995b) , 
RT-MKC442 (Hopkins et al., 1996) and RT-delavirdine (Esnouf et al., 1997) . The same analysis was used for HI-240, HI-241, HI-253, HI-280 and HI-281, which were docked into the NNI binding site. The molecular surface of the protein and the molecular surface of the inhibitor (Connolly, 1983) were considered to be in contact when the distances between them were within 1 Å. Different colours were assigned to the binding pocket surface based on the distance between the protein surface and the molecular surface of the inhibitor (Figure 2 ). In the case of the V106A mutant, two terminal methyl groups [C(1γ)H3 and C(2γ)H3] were used to calculate the contribution of V106 to the van der Waals contact with the NNI and are coloured in red (Figure 2 ).
Compounds
The general procedures for the synthesis of S-DABO derivatives, HI-280 and HI-281 (Vig et al., 1998b) , and PETT derivatives HI-236, HI-240, HI-241 and HI-253 (Vig et al., 1998a) , have previously been reported. MKC-442 was synthesized according to literature procedures (Danel et al., 1996; Tanaka et al., 1991) , as was trovirdine (Cantrell et al., 1996) . Delavirdine was purchased from Pharmacia & Upjohn (Bridgewater, N.J., USA). Nevirapine was purchased from Roxane Laboratories (Columbus, Ohio, USA). Zidovudine was purchased from Toronto Research Chemicals (Toronto, Canada). Analytical data for S-DABO compounds (Vig et al., 1998b) and PETT compounds (Vig et al., 1998a) have been previously reported except for our lead compound, HI-236, which is listed below. HI-236 and HI-241 were further characterized by X-ray crystallography ( Figure 3b and c) (experimental details will be published elsewhere). 151.8, 151.7, 146.5, 140.9, 128.1, 117.7, 113.3, 112.6, 111.2, 110.9, 55.7, 55.5, 45.6 and 29.9 . UV (MeOH): λmax: 202, 205, 231, 276 and 300 nm; IR (KBr disc) υ 3209, 3152, 3078, 3028, 2951, 2831, 1595, 1533, 1468, 1306, 1227, 1095, 1059, 1022, 862, 825, 796, 707 cm Purified RT assays and p24 assays measuring anti-HIV activity NNI compounds were tested for RT inhibitory activity using purified recombinant HIV RT (cell-free assay, IC 50 [rRT]) and using HIV-1-infected normal human PBMCs (IC 50 [p24]) as previously described (Vig et al., 1998a) . The NNIs are shown as stick models: white is carbon; blue is nitrogen; red is oxygen; magenta is hydrogen; and green is bromine or sulphur. The molecular surfaces of the compounds were prepared and colour-coded based on distance calculations between the molecular surface of the NNI binding pocket and the molecular surface of the inhibitor using the GRASP program (Nicholls, 1992) . The blue molecular surface is in van der Waals contact with RT residues. The yellow surface area is not in van der Waals contact with RT. The red shows decreased van der Waals contact with RT when V106 is mutated to alanine (MDR RT). Docked molecules include (a) HI-240; (b) HI-236; (c) HI-280; (d) HI-281; (e) nevirapine; (f) delavirdine; and (g) MKC-422; (a) and (b) show a low van der Waals contact loss (red region, see Table 1 ); (c) and (d) show a large van der Waals contact loss, especially for the alkylthio group.
HIV-1 mutant strains
The following reagents were obtained through the AIDS Research and Reference Reagent Program (NIAID, NIH, Bethesda, Md., USA); HIV-1 A17 variant (K103N and Y181C) from E Emini (Nunberg et al., 1991) ; nevirapineresistant HIV-1 (A17, Y181C) from D Richman (Richman et al., 1991) ; and HIV-1 RTMDR1 from B Larder (Larder et al., 1993) .
Results and Discussion
Analysis of selective resistance of V106A mutant of HIV RT First, we selected a panel of NNI compounds that showed excellent anti-RT activities and were tested against the multidrug-resistant (V106A) mutant strain. Interestingly, the activities of these compounds against the RT multidrug-resistant strain were strikingly different from each other. Our S-DABO compounds HI-280 and HI-281 showed significantly lower potency against the V106A RT strain than our PETT derivatives HI-240, HI-240, HI-253 and HI-236, which show slightly lower activity relative to wild-type RT.
The V106 residue is situated in between wing 1 and wing 2 regions of the NNI binding site of RT, but closer to wing 1. The two terminal methyl groups of V106 are in hydrophobic contact with NNI compounds as specifically illustrated by the red regions in Figure 2 . The aromatic ring of nevirapine loses most of the van der Waals contact with V106 in the wing 1 region of the binding pocket when V106 is mutated to an alanine (Figure 2e ). The V106 residue also provides hydrophobic contact with the middle portion of the delavirdine molecule (partly with the fivemembered ring and partly with the linker group of the molecule). The loss of van der Waals contact and thus lower binding affinity with the binding pocket may explain why the MDR strain (V106A) shows considerable resistance to both nevirapine and delavirdine. We hypothesized that the examination of how the hydrophobic contact loss may be correlated with the striking difference in resistance to S-DABO and PETT derivatives would help us to understand the structural basis of the resistance. We calcu- lated the contribution of the van der Waals contact between the S-DABO or PETT compounds and the V106 residue (see Materials and Methods) as shown in Table 1 . These values reflected the net loss of interactions between the compounds and RT when V106 is mutated to alanine. The extent of the resistance appears to be correlated with the contact loss, although it probably is not the sole factor determining the resistance. Further analysis revealed that the extensive contact of the V106 residue with the alkylthio group of S-DABO provides additional van der Waals contact and therefore results in a larger loss of van der Waals contact upon mutation than for the PETT compounds. The van der Waals contact that V106 provides for the S-DABO compounds may help position the alkylthio group in a favourable conformation, more so than for PETT derivatives. As we have previously reported , when HEPT derivatives such as MKC-442 and S-DABO derivatives are superimposed and docked into the NNI binding site of RT, the alkoxy group of MKC-442 resides in the same location as the alkylthio group of the S-DABO compound. Based on this observation and on modelling studies, MKC-442 also would be expected to lose contact with the binding site of the RT mutant to an extent similar to that predicted for S-DABO, and would show poor inhibition of the RT mutant, as did the S-DABO compounds. Indeed, MKC-442 showed a 100-fold reduced inhibitory activity against the MDR mutant strain. Taken together, PETT derivatives were observed to have an inherent advantage over S-DABO compounds against the V106A mutant because PETT compounds form more favourable contacts with the binding pocket.
Resistance of Y181C mutant HIV RT to inhibition by NNIs: design of HI-236
Most NNI compounds we evaluated contain an aromatic group that interacts with the wing 2 region of RT, (Y181 or Y188) (Kroeger Smith et al., 1995) . This interaction contributes to the binding affinity of NNI compounds. The Y181 stacking interaction is lost in the Y181C mutant, which is resistant to inhibition by nevirapine (IC 50 >100 µM, The synthesis of HI-240, HI-241, HI-253, HI-280, HI-281 and their activities against the WT RT-expressing IIIB strain of HIV-1 were recently reported Vig et al., 1998a,b) . *MS, molecular surface area calculated using Connolly's MS program (Connolly, 1983) . Defined as boundary of volume within any probe sphere (meant to represent a water molecule) of given radius sharing no volume with hard sphere atoms which make up the molecule. Values are slightly smaller than those approximated by LUDI program. †MS loss, decreased molecular surface contact between the inhibitor and MDR RT residues relative to wild-type RT. ‡The activity of the lead compound HI-236 against the RT MDR strain of HIV-1 was confirmed in three independent experiments. ND, the values for reference compounds were not calculated. compounds, which show significant potency against wild type (WT) RT, still show significant activity against the Y181C mutant even after a 100-300-fold decrease in activity relative to WT RT. From our previous modelling studies on PETT derivatives, using a modified score function (Vig et al., 1998a) , we quantified the loss of activity owing to unfavourable substitution of PETT derivatives by a hydrophilic group at the para-position, near the ring plane of the W229 residue of RT. Depending on the nature of the interaction, the unfavourable interaction is reflected by a decrease in the estimated K i value by five times when a moderate hydrophilic group such as methoxy was near an aromatic ring and by 100 times when a more strongly hydrophilic group was near an aromatic ring (see Materials and Methods). This same principle can be used to study the resistance of NNI by RT mutants. The Y181C mutant alters the favourable π-stacking interaction to an unfavourable interaction between an aromatic group of the NNI and a hydrophilic group (SH) of cysteine, which will lead to an approximately 100-fold increase in resistance. This estimation is consistent with the resistance observed for HI-240 (300-fold increase). Our calculations are not consistent, however, with the ability of the Y181C mutant to have 10-100-fold additional resistance to S-DABO compounds and delavirdine, but have less resistance to PETT compounds. This indicates that there may be other factors involved in drug resistance by RT that are not accounted for in our modelling.
How can we make a compound more potent against RT mutants based on a lead compound such as HI-240 by adding larger groups on HI-240 to interact with the wing 2 region? These designs should be based on an understanding of the molecular mechanism underlying NNI resistance. First, based on our modelling studies using RT crystal structures and considering the more complete picture provided by the recently published RT-DNA-dNTP structure (Huang et al., 1998) , an important factor was revealed that may contribute to the interpretation of the mechanism of NNI resistance. This involves how the binding of NNIs force RT residue W229 to change its position slightly and residues Y181 and Y188 to rotate into another rotamer conformation. Consequently, the binding pocket is substantially larger than it was before NNI binding, which forces the primer-template into an inactive binding conformation and renders the protein inactive (Huang et al., 1998) . The volume change is a direct consequence of the different positions of the Y181, Y188 and W229 side chains before and after the NNI binding. When Y181 and Y188 are mutated to cysteine residues, the volume change due to NNI binding is smaller and the impact of NNI inhibiting the RT mutants would thus be attenuated. Therefore, we postulate that an ideal NNI compound that (a) is highly potent against wild-type RT and thus can afford a considerable activity loss against mutants (i.e. a picomolar-level inhibitor against wild-type RT may still be effective against RT mutants at nanomolar concentra- Vig et al., 1998a,b) . *rRT, recombinant RT. †The IC 50 values of HI-236 and HI-240 against IIIB with WT RT were <0.001 in each of three independent experiments. The activity of HI-236 against drug resistant HIV-1 strains was confirmed in four independent experiments. The activity of HI-240 against drug resistant HIV-1 strains was examined in three independent experiments. ‡The lack of activity (IC 50 >100 mM) of HI-280 against drug-resistant HIV-1 strains was confirmed in three independent experiments. ND, not determined. tions); and (b) maximizes the occupancy at wing 2 region, will most likely have an advantage against the wing 2 mutants, such as the especially problematic Y181C RT mutant. Such theory adds another strategy to a recent finding that a flexible functional group at wing 2 region may result in NNI compounds more potent against the Y181 mutant of RT (Hsiou et al., 1998) . Based on our composite binding pocket model, we previously recognized that the wing 2 region has a substantial molecular volume of approximately 160 Å 3 surrounding the phenyl ring at the wing 2 region, which defines space that can potentially be more efficiently occupied by a larger functional group . We thought that this strategy could improve inhibitor potency against wild-type RT and may provide a better inhibition profile against wing 2 mutants of RT. This prompted us to synthesize HI-236, which contains one methoxy group at the 2′ position (same position as the fluoro atom of HI-240) and another methoxy group at the 5′ position of the phenyl ring, which can contact the wing 2 region (see Figure 2g and Figure 3 ).
HI-236 was docked into the NNI binding site of RT using a molecular docking procedure in the Affinity module within the Insight II program. Docking of the compound into the NNI binding site required the use of X-ray coordinates of an RT-NNI complex (in this case the RT-9-Cl-TIBO complex was used) (Ren et al., 1995a) . The docking studies indicated that the 2-methoxy group of HI-236 was situated beneath the ethyl linker and fit favourably into a cavity of the binding pocket, providing contact with protein residues that cannot be achieved by HI-240. Likewise, the 5-methoxy group of HI-236 provides close contact with residues P95 and W229, and is near Y181, leaving less unoccupied space (135 Å 3 ) at wing 2. Based on our established procedure using a modified LUDI score function (Vig et al., 1998a) , the estimated K i value of HI-236 (0.1 µM) was better than that of HI-240 (0.7 µM) (Vig et al., 1998a) . Like HI-240, HI-236 elicited potent anti-HIV activity with IC 50 values less than 0.001 µM in three out of three independent experiments, which was consistently lower than the IC 50 values for zidovudine (0.004 µM). Furthermore, the IC 90 value of our HI-236 (9 nM) was 10-fold better than that of zidovudine (100 nM). Neither HI-240 nor HI-236 were cytotoxic at concentrations up to 100 µM. Therefore, the calculated selectivity index (IC 50 [MTA]/IC 50 [p24]) of HI-236 was >10 5 . Remarkably, HI-236 demonstrated an IC 50 value of 0.005 µM against MDR RT (which may be slightly better than for HI-240), 0.1 µM against Y181C mutant (three times better than for HI-240), and 8 µM against Y181C plus K103N (four times better than for HI-240). This result was consistent with our predictions that HI-236 would be a more potent anti-HIV compound than HI-240 against RT mutants. Our strategy, which included the utilization of potentially unoccupied space in the wing 2 region of the NNI binding site of RT by including two methoxy groups on the phenyl ring of HI-236, was found to be effective.
K103N mutant of HIV RT
A commonly observed RT mutant is K103N, which has an altered residue charge that may change the local structure and could be critical for stabilization of the K101 loop. The K101 loop is in close contact with nevirapine and delavirdine and any alteration in this region can cause weaker binding resulting in resistance to these drugs. The same resistance mechanism holds for our PETT derivatives and resulted in an additional 100-fold reduction observed in the test against the double mutant Y181C plus K103N (Table 2 ). In the future we will continue to use our NNI binding pocket model of RT to modify our compounds with the goal of inhibiting other clinically observed NNIresistant mutants of HIV RT.
